Literature DB >> 2025311

Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis.

E Hawrylko1, A Spertus, C A Mele, N Oster, M Frieri.   

Abstract

Peripheral blood mononuclear cells (PBMC) from patients with systemic sclerosis (SSc) produced increased amounts of interleukin-2 (IL-2), in a dose-dependent manner, in response to stimulation with human type I collagen, whereas PBMC from normal subjects did not. At a dose of 50 micrograms human type I collagen/10(6) PBMC, PBMC from SSc patients (n = 17) produced 8 times as much IL-2 as did PBMC from 16 normal subjects (P less than 0.005) and 3 times as much as did PBMC from a group of 13 rheumatoid arthritis patients (P less than 0.05). In contrast, IL-2 production by PBMC after nonspecific stimulation with the mitogen, phytohemagglutinin, did not differ among the SSc, rheumatoid arthritis, and normal control groups. Cell depletion experiments indicated that the IL-2-producing cells in SSc patients are CD4+. Thus, SSc patients have CD4 cells that are specifically sensitized to human type I collagen and can produce increased levels of IL-2. Measurement of IL-2 production stimulated by human type I collagen may be useful in evaluating disease activity, and further investigation of this process may contribute to the delineation of the pathogenesis of SSc.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025311     DOI: 10.1002/art.1780340510

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.

Authors:  Thomas M Chiang; Arnold E Postlethwaite
Journal:  Biochim Biophys Acta       Date:  2007-04-18

2.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 3.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 4.  A brief overview of the pathogenesis of scleroderma (systemic sclerosis).

Authors:  E C LeRoy
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.

Authors:  T Thomas; U B Gunnia; E J Yurkow; J R Seibold; T J Thomas
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis.

Authors:  P P Sfikakis; J Tesar; S Theocharis; G L Klipple; G C Tsokos
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

7.  Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.

Authors:  Monica Brown; Arnold E Postlethwaite; Linda K Myers; Karen A Hasty
Journal:  Clin Rheumatol       Date:  2012-02-25       Impact factor: 2.980

8.  Characterisation of the immune response to type I collagen in scleroderma.

Authors:  Kenneth J Warrington; Usha Nair; Laura D Carbone; Andrew H Kang; Arnold E Postlethwaite
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 9.  Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.

Authors:  Yoshihito Shima
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.